간행물

대한간학회> Clinical and Molecular Hepatology(대한간학회지)

Clinical and Molecular Hepatology(대한간학회지) update

Clinical and Molecular Hepatology (CMH)

  • : 대한간학회
  • : 의약학분야  >  내과학
  • : KCI등재
  • : SCOPUS
  • : 연속간행물
  • : 계간
  • : 2287-2728
  • : 2287-285x
  • : 대한간학회지()→Korean Journal of Hepatology(2004~)→대한간학회지(2012~)

수록정보
수록범위 : 1권1호(1995)~26권3호(2020) |수록논문 수 : 4,636
Clinical and Molecular Hepatology(대한간학회지)
26권3호(2020년 07월) 수록논문
최근 권호 논문
| | | |

KCI등재 SCOPUS

1Management of liver diseases during the pandemic of coronavirus disease-19

저자 : Ju-yeon Cho , Soon Sun Kim , Young-sun Lee , Do Seon Song , Jeong-hoon Lee , Ji Hoon Kim

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 26권 3호 발행 연도 : 2020 페이지 : pp. 243-250 (8 pages)

다운로드

(기관인증 필요)

초록보기

KCI등재 SCOPUS

2Unmet needs of chronic hepatitis C in the era of directacting antiviral therapy

저자 : Chung-feng Huang , Ming-lung Yu

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 26권 3호 발행 연도 : 2020 페이지 : pp. 251-260 (10 pages)

다운로드

(기관인증 필요)

초록보기

The treatment of chronic hepatitis C (CHC) has been revolutionized in an era of all-oral direct-acting antivirals (DAAs) since 2014. Satisfactory treatment efficacy and tolerability can be provided by novel DAAs. Nevertheless, there are still some unmet needs and emerging issues in the treatment of CHC in the DAA era. Certain hard-to-cure populations are prone to have inferior treatment responses, including patients with severe liver decompensation, active hepatocellular carcinoma (HCC), and hepatitis C virus (HCV) genotype 3 (HCV-3) infection and those who experience multiple DAA treatment failures. Hepatitis B virus (HBV) reactivation during and after DAA treatment has raised concern regarding the use of prophylactic antivirals against HBV throughout DAA treatment. However, the standard strategy for the use of prophylactic antivirals is not uniform across regional guidelines. In the post-sustained virological response (SVR) period, HCC still occurs in a substantial proportion of patients. Due to the relatively short follow-up period, the net benefit of the achievement of an SVR by DAAs in the reduction of extrahepatic manifestations has not yet been determined. Attention must also be paid to HCV reinfection, particularly in high-risk populations. The most critical and unmet need for HCV elimination is the large gap in the HCV care cascade at the population level. To accomplish the World Health Organization (WHO)'s goal for HCV elimination by 2030, the expansion of access to HCV care requires a continuous effort to overcome practical and political challenges. (Clin Mol Hepatol 2020;26:251-260)

KCI등재 SCOPUS

3Novel biomarkers for the management of chronic hepatitis B

저자 : Takako Inoue , Yasuhito Tanaka

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 26권 3호 발행 연도 : 2020 페이지 : pp. 261-279 (19 pages)

다운로드

(기관인증 필요)

초록보기

Hepatitis B virus (HBV) cannot be eliminated completely from infected hepatocytes because of the presence of intrahepatic covalently closed circular DNA (cccDNA). As chronic hepatitis B (CHB) can progress to cirrhosis and hepatocellular carcinoma (HCC), it is important to manage CHB to prevent HCC development in high-risk patients with high viral replicative activity or advanced fibrosis. Serum biomarkers are noninvasive and valuable for the management of CHB. Hepatitis B core-related antigen (HBcrAg) correlates with serum HBV DNA and intrahepatic cccDNA. In CHB patients with undetectable serum HBV DNA or loss of HBsAg, HBcrAg still can be detected and the decrease in HBcrAg levels is significantly associated with hopeful outcomes. Therefore, HBcrAg can predict HCC occurrence or recurrence. Measurement of the Mac-2 binding protein glycosylation isomer (M2BPGi) has been introduced for the evaluation of liver fibrosis. Because elevated M2BPGi in CHB is related to liver fibrosis and the prediction of HCC development, monitoring its progression is essential. Because alpha fetoprotein (AFP) has insufficient sensitivity and specificity for early-stage HCC, a combination of AFP plus protein induced by vitamin K absence factor II, or AFP plus Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein might improve the diagnosis of HCC development. Additionally, Dickkopf-1 and circulating immunoglobulin G antibodies are the novel markers to diagnose HCC or assess HCC prognosis. This review provides an overview of novel HBV biomarkers used for the management of intrahepatic viral replicative activity, liver fibrosis, and HCC development. (Clin Mol Hepatol 2020;26:261-279)

KCI등재 SCOPUS

4Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis

저자 : Le Thi Thanh Thuy , Hoang Hai , Norifumi Kawada

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 26권 3호 발행 연도 : 2020 페이지 : pp. 280-293 (14 pages)

다운로드

(기관인증 필요)

초록보기

Cytoglobin (Cygb), a stellate cell-specific globin, has recently drawn attention due to its association with liver fibrosis. In the livers of both humans and rodents, Cygb is expressed only in stellate cells and can be utilized as a marker to distinguish stellate cells from hepatic fibroblast-derived myofibroblasts. Loss of Cygb accelerates liver fibrosis and cancer development in mouse models of chronic liver injury including diethylnitrosamine-induced hepatocellular carcinoma, bile duct ligation-induced cholestasis, thioacetamide-induced hepatic fibrosis, and choline-deficient L-amino aciddefined diet-induced non-alcoholic steatohepatitis. This review focuses on the history of research into the role of reactive oxygen species and nitrogen species in liver fibrosis and discusses the current perception of Cygb as a novel radical scavenger with an emphasis on its role in hepatic stellate cell activation and fibrosis. (Clin Mol Hepatol 2020;26:280- 293)

KCI등재 SCOPUS

5Fecal microbiota transplantation in alcohol related liver diseases

저자 : Saggere Muralikrishna Shasthry

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 26권 3호 발행 연도 : 2020 페이지 : pp. 294-301 (8 pages)

다운로드

(기관인증 필요)

초록보기

The current standard of care for severe alcoholic hepatitis (SAH) has several limitations in that only up to one-third of patients are eligible for steroid therapy. Additionally, steroids have their own issues: a portion of patients do not respond, while there is doubtful long-term benefit in those who do and a large proportion are ineligible to receive steroids entirely and hence have no definitive options for treatment. As such, there is a large gap between the problem and the available solutions. Alcohol causes dysbiosis and also disrupts gut barrier function, consequently promoting the translocation of microbial lipopolysaccharide into the portal circulation and liver. Therefore, probiotics, prebiotics, antibiotics, or transplantation of gut microbiota are likely to attenuate the dysbiosis-related liver insult. Fecal microbiota transplantation (FMT) is expected to have a role in managing alcoholic liver disease in general and SAH in particular by correcting dysbiosis, the primary insult. Results from mouse studies have suggested beyond doubt that alcohol-related liver injury is transferrable and also treatable by adopting FMT from suitable donors. Initial human trials from our center have affirmed benefits in human subjects with SAH as well, with both improvements in disease severity and as well as the rate of survival. Further studies addressing the head-to-head comparison of steroids and FMT are ongoing. Available preliminary data are promising and FMT and/or gut microbial modulation might become the standard of care in the near future for managing alcohol-related liver diseases, especially alcoholic hepatitis, with greater applicability, improved acceptability, and minimal side effects. (Clin Mol Hepatol 2020;26:294-301)

KCI등재 SCOPUS

6Is liver biopsy still useful in the era of non-invasive tests?

저자 : Tae Seop Lim , Ja Kyung Kim

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 26권 3호 발행 연도 : 2020 페이지 : pp. 302-304 (3 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재 SCOPUS

7Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma

저자 : Sojung Han , Do Young Kim

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 26권 3호 발행 연도 : 2020 페이지 : pp. 305-308 (4 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재 SCOPUS

8Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?

저자 : So Yeon Kim

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 26권 3호 발행 연도 : 2020 페이지 : pp. 309-311 (3 pages)

다운로드

(기관인증 필요)

초록보기

다운로드

(기관인증 필요)

초록보기

KCI등재 SCOPUS

10Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change?

저자 : Jung Hee Kim , Dong Hyun Sinn

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 26권 3호 발행 연도 : 2020 페이지 : pp. 315-317 (3 pages)

다운로드

(기관인증 필요)

초록보기
12
권호별 보기
가장 많이 인용된 논문

(자료제공: 네이버학술정보)

가장 많이 인용된 논문
| | | |
1연안해역에서 석유오염물질의 세균학적 분해에 관한 연구

(2006)홍길동 외 1명심리학41회 피인용

다운로드

2미국의 비트코인 규제

(2006)홍길동심리학41회 피인용

다운로드

가장 많이 참고한 논문

(자료제공: 네이버학술정보)

가장 많이 참고한 논문

다운로드

2미국의 비트코인 규제

(2006)홍길동41회 피인용

다운로드

해당 간행물 관심 구독기관

마산대학교 고려대학교 성균관대학교 연세대학교 백석대학교
 28
 19
 16
 7
 7
  • 1 마산대학교 (28건)
  • 2 고려대학교 (19건)
  • 3 성균관대학교 (16건)
  • 4 연세대학교 (7건)
  • 5 백석대학교 (7건)
  • 6 부산광역시청 (7건)
  • 7 서울대학교 (6건)
  • 8 전주대학교 (5건)
  • 9 대구한의대학교(구 경산대학교) (4건)
  • 10 성신여자대학교 (4건)

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기